# Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder

> **NCT04884763** · PHASE2 · COMPLETED · sponsor: **Indiana University** · enrollment: 30 (actual)

## Conditions studied

- Temporomandibular Disorder

## Interventions

- **DRUG:** Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments
- **DRUG:** Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments

## Key facts

- **NCT ID:** NCT04884763
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-15
- **Primary completion:** 2024-01-04
- **Final completion:** 2024-01-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04884763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04884763, "Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04884763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*